Case Report

Genetic Analysis of a Family with Multiple Incidences of Prostate Cancer

Ninghan Feng^a Fengping Liu^b Xinyu Xu^a Yang Wang^a
Qingsong Sheng^c Kuichun Zhu^c

^aDepartment of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi, China; ^bWuxi School of Medicine, Jiangnan University, Wuxi, China; ^cShenrui Biopharmaceuticals, R&D, Wuxi, China

Keywords

Prostate cancer · Predisposition · Genetic · Mutation · Germline

Abstract

A family with multiple members diagnosed with prostate cancer was identified, and genetic variants were analyzed. Three brothers were diagnosed with prostate cancer. Germline variants in *BRCA1*, *BRCA2*, *TINF2*, and *CD19* were found through next-generation DNA sequencing using a hereditary cancer panel. The *BRCA1* G275D variant was present in patients, but absent in the healthy member. An *ELAC2* variant was found in 1 patient. Several mutations were predicted to be deleterious by a set of computation programs. Multiple gene mutations might contribute to the overall predisposition to prostate cancer in the family. Even in cases with potentially deleterious variants in *BRCA1* or *BRCA2*, there could be diverse clinical manifestations.

© 2022 The Author(s).

Published by S. Karger AG, Basel

Introduction

Prostate cancer (Pca) is one of the most common cancers in men in the USA. In China, Pca is among the top 10 of the most common cancers in men [1]. About 10% of Pca was considered hereditary [2, 3]. Some common genes of which mutations cause predisposition to Pca include *BRCA1*, *BRCA2*, *CHEK2*, *ATM*, *HOXB13*, *BRIP*, *PALB2*, and mismatch repair genes (MMR) [2–4]. The American College of Medical Genetics recommend genetic testing when three or more first-degree relatives are with Pca or two or more first-degree relatives

Correspondence to:
Ninghan Feng, n.feng@njmu.edu.cn
Kuichun Zhu, kzhu68@hotmail.com

Fig. 1. Family pedigree. *This subject was out of contact.

Table 1. Distribution of rare germline variants from NGS

Subject	<i>BRCA1</i> NM_007300 p.G275D	<i>BRCA2</i> NM_000059 p.V2109I	<i>TINF2</i> NM_001099274 p.T100I	<i>CD19</i> NM_001178098 p.P471L	Others
N1	–	+	+	+	<i>MSH3</i> NM_002439:p.D620N
P1	+	+	+	+	
P2	+	+	+	+	<i>ELAC2</i> NM_018127:p.R464W

All variants were of heterozygous type.

N1, healthy brother; P1 and P2, two brothers with Pca.

*Mutation present.

–Mutation absent.

are diagnosed with Pca at age 55 or younger [5]. We performed genetic analysis of a family in which three out of four brothers suffered from Pca and found variants in *BRCA1* and *BRCA2*, together with some other putatively related genes, and the clinical characteristics also less aggressive.

Case Report

Two brothers were diagnosed with Pca in 2020 at the local hospital through prostate biopsies and pathological exams. Main symptom is difficulty in urination. History tracing revealed that another brother from the family was also diagnosed with Pca a few years ago, but lost contact since then. Pca was not diagnosed before the age of 60. One brother remains healthy. The family pedigree is shown in Figure 1.

Blood specimens were taken from the three brothers available for genetic tests with consent. NGS was performed with a hereditary panel of 219 predisposition genes in cancers. The gene list of the panel and experimental details are provided in online supplementary file S1 (for all online suppl. material, see www.karger.com/doi/10.1159/000521122). Six rare germline gene variants were identified, and all were of heterozygous type (Table 1). All variants were verified by Sanger sequencing. No other variants were found in *CHEK2*, *ATM*, *BRIP1*, *PALB2*, *HOXB13*, or other MMR genes. Panel gene list, NGS experimental, and bioinformatics details are given in online supplementary File 1. *BRCA1* G275D was noticeably absent in the healthy brother but present in the two brothers with Pca, while *BRCA1* V2109I was found in all the three brothers (Table 1).

Table 2. Population frequencies of the variants

Gene	SNP rs#	ChinaMAP	1000G EAS	ExAC EAS	GenomeAD EAS
<i>BRCA1</i>	rs397509327	0.00179448	NA	0.0014	0.0011
<i>BRCA2</i>	rs79456940	0.00236116	0.002	0.0038	0.0032
<i>CD19</i>	rs147626581	NA	NA	0	0
<i>ELAC2</i>	rs200149324	0.0083113	0.0109	0.0093	0.0103
<i>MSH3</i>	rs200337887	0.000708349	NA	0.0006	0.0006
<i>TINF2</i>	NA	NA	NA	NA	NA
NA, information not found.					

Table 3. Functional effect prediction by computational programs

Variant	SIFT	Polyphen2	MutationTaster	MutationAssessor	Provean
<i>BRCA1</i> G275D	D	B	D	H	D
<i>BRCA2</i> V2109I	T	B	N	N	N
<i>CD19</i> P471L	D	D	N	L	D
<i>ELAC2</i> R464W	D	D	N	M	D
<i>MSH3</i> D620N	D	D	D	M	D
<i>TINF2</i> T100I	D	P	D	M	D
D, damaging; P, probably damaging; T, tolerant; B, benign; N, neutral; M, moderate; L, low; H, high.					

All variants were rare with population allele frequencies between 0.001 and 0.01 (Table 2). Population frequency information for *TINF2* was absent from the databases. NGS data from over 200 Pca patients collected in the laboratory were also analyzed, and the *BRCA1* variant was found in another patient with Pca, and no other *BRCA1* or *BRCA2* variant was found recurrent except the family in this report.

The functional consequences of the variants were analyzed by some commonly used in silico tools, SIFT, Polyphen2, MutationTaster, MutationAssessor, and Provean [6]. The predicted effects are summarized in Table 3. The results show that the *BRCA1* G275D might have a higher functional impact, and the *BRCA2* V2109I might have limited functional effect. The glycine at position 275 of *BRCA1* is conserved among multiple species, including human, monkey, and mouse (data not shown). None of the variants was classified as *pathogenic* or *likely pathogenic* in the Clinvar database (<https://www.ncbi.nlm.nih.gov/clinvar/>).

In this family, Pca was not diagnosed before the age of 60. One brother remains healthy at the age over 70. The two brothers with Pca with clinical information available had adenoma of the prostate by pathological exams, and the Gleason scores were 6 and 7, respectively. No metastasis was found. PSA level was between 4 and 10 ng/mL. Both received radical prostatectomy treatment, and the disease remain stable with PSA less than 4 ng/mL up to the point of this report.

Discussion/Conclusions

BRCA1 and *BRCA2* genes are tumor suppressors, involved in cellular DNA damage repair. *BRCA1* and *BRCA2* gene germline mutations are the most common and major drivers of familial Pca [2–4, 7, 8]. The types of *BRCA2* gene germline mutations include frameshift (64%),

missense (31%), and splicing (5%). For the *BRCA1* gene, the mutation types are missense (63%), frameshift (31%), and splicing (6%) [7]. It is estimated that germline mutations of *BRCA1* and *BRCA2* could increase Pca risk by 3.8- and 8.6-fold, respectively [9, 10]. Clinically, Pcas in *BRCA*-mutated carriers are associated with early onset, higher Gleason score, more aggressive clinical course, and shorter survival time [9, 11, 12]. Pca patients with mutations in DNA damage repair genes respond favorably to PARP inhibitors such as olaparib and rucaparib [13]. In this family however, the onset of age is older than 60 years old. Gleason scores and PSA level were at moderate levels. Aggressive clinical features were not shown.

In summary, multiple brothers in this family were diagnosed with Pca, and *BRCA1* G275D appeared having high impact on the pathogenesis. Early onset and aggressive clinical manifestations did not display in this family. It appears that at least in some families, variants in multiple genes might contribute together to the predisposition to Pca, and even in cases with potentially deleterious variants in *BRCA1* or *BRCA2*, there could be diverse clinical manifestations.

Acknowledgments

Authors would like to thank Peng Jiang, Wenhong He, Yao Yao, and Lushuai Yao for assistance in the material collection and analysis.

Statement of Ethics

The subjects of this case report have given their written informed consent for the study and for publication of the research findings. The study was approved by the Ethics Committee of Affiliated Wuxi No. 2 Hospital, Nanjing Medical University.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

The study was supported in part by Jiangsu Social Development Grant, BE2018629 (N.H.F.).

Author Contributions

Project conception and overall organization of the research: N.H.F., F.P.L., and Q.S.S.; clinical materials and information collection: X.Y.X. and Y.W.; experimental design and performing data analysis and manuscript preparation: K.C.Z.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding authors.

References

- 1 Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. *Nat Rev Urol*. 2021;18(5):282–301.
- 2 Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, et al. Hereditary prostate cancer: genes related, target therapy and prevention. *Int J Mol Sci*. 2021;22(7):3753.
- 3 Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, et al. Genetic testing for hereditary prostate cancer: current status and limitations. *Cancer*. 2018;124(15):3105–17.
- 4 Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R. Prostate cancer germline variations and implications for screening and treatment. *Cold Spring Harb Perspect Med*. 2018;8(9):a030379.
- 5 Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, et al., Guideline Development Group. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med*. 2015;17(1):70–87.
- 6 Pshennikova VG, Barashkov NA, Romanov GP, Teryutin FM, Solov'ev AV, Gotovtsev NN, et al. Comparison of predictive in silico tools on missense variants in GJB2, GJB6, and GJB3 genes associated with autosomal recessive deafness 1A (DFNB1A). *ScientificWorldJournal*. 2019;2019:5198931.
- 7 Brandao A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. *Int J Mol Sci*. 2020;21(14):5036.
- 8 Doan DK, Schmidt KT, Chau CH, Figg WD. Germline genetics of prostate cancer: prevalence of risk variants and clinical implications for disease management. *Cancers*. 2021;13(9):2154.
- 9 Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol*. 2013;31(14):1748–57.
- 10 Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. *Br J Cancer*. 2012;106(10):1697–701.
- 11 Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clin Cancer Res*. 2010;16(7):2115–21.
- 12 Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, et al. BRCA-associated cancers: role of imaging in screening, diagnosis, and management. *Radiographics*. 2017;37(4):1005–23.
- 13 Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP inhibitors and prostate cancer: to infinity and beyond BRCA. *Oncologist*. 2021;26(1):e115–29.